Stroke
Conditions
Interventions
Active rTMS group:Active rTMS. An "8" shape coil is used to target the healthy side M1 area of the subject.
Treatment parameters: Frequency 1 Hz, 80% of the RMT (Resting Motor Threshold), stimulation
Sham rTMS group:Sham rTMS.The operation steps, stimulation sites, and treatment parameters of the sham stimulation group are the same as those of the active stimulation group. However, during the trea
Healthy control group:None
Sponsors
The First Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients: (1) Age between 18 and 80 years; (2) Right-handed (Edinburgh Handedness Inventory); (3) First occurrence of unilateral hemorrhagic or ischemic stroke confirmed by CT or MRI; (4) Duration of illness ranging from 1 week to 6 months; (5) Initial Fugl-Meyer Upper Limb Motor Function Assessment (FMA-UE) score < 58 points (maximum 66 points), accompanied by upper limb motor dysfunction; (6) Voluntary participation, able to cooperate with the research process and sign the informed consent form. Inclusion criteria for healthy subjects: (1) Age between 18 and 80 years; (2) Right-handed (Edinburgh Handedness Inventory); (3) Voluntary participation, able to cooperate with the research process and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) History of epilepsy or family history of epilepsy; (2) Head and neck area contains conductive, ferromagnetic or other magnetic-sensitive metals, or there is a pacemaker in the heart; (3) Received rTMS treatment within the past 3 months; (4) Has cerebellar hemorrhage, subarachnoid hemorrhage or transient ischemic attack; (5) Condition is unstable, progressive stroke or cerebral infarction leads to cerebral hemorrhage; (6) Has hematological diseases/severe internal medical diseases; (7) Pregnant women; (8) Has a history of alcohol dependence, neurological diseases and other complex mental disorders; (9) Uses drugs that affect the activity of the central nervous system, such as benzodiazepines or muscle relaxants such as baclofen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FMA-UE (Fugl-Meyer Assessment Upper Extremity) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| WMFT (Wolf Motor Function Test, WMFT) score;MBI (Modified Barthel Index, MBI) score;MAS (Modified Ashworth Scale, MAS) score;hdEEG (High-density electroencephalogram);TEPs (TMS-evoked potentials);ERSP (Event-related spectral perturbation);LMFA-AUC (Local mean field amplitude);SCD (Significant current density);SOE (Significant oscillation envelope);SCS (Significant current scattering);SEM(Structural equation model); | — |
Countries
China
Contacts
Public ContactHua Yuan
The First Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed